Individual who has undergone mainstreamed and / or private genetic testing for cancer predisposition genes (A/P-AFF)
(Adult and Paediatric Conditions in AFFECTED Patients)
Emergency referrals
If any of the following are present or suspected, refer the patient to the emergency department (via ambulance if necessary) or seek emergent medical advice if in a remote region.
- No referrals to emergency relating to genetic testing or review
Does your patient wish to be referred?
Minimum referral criteria
Does your patient meet the minimum referral criteria?
Category 1
Appointment within 30 days is desirable
- Patients with breast cancer referred for genetic counselling and confirmation of an identified mutation in a cancer predisposition gene where the results will influence local or systemic treatment considerations
- Patients with ovarian cancer or any other cancer associated with poor prognosis referred for:
- confirmation of an identified mutation in a cancer predisposition gene
- genetic counselling regarding an identified unclassified variant in a cancer predisposition gene
- clinical suspicion of a cancer predisposition syndrome and negative genetic testing
Category 2
Appointment within 90 days is desirable
- Patients with an identified mutation in a cancer predisposition gene not fulfilling Category 1 criteria
Category 3
Appointment within 365 days is desirable
- Patients referred for genetic counselling regarding an identified mutation/variant in a gene of low or unknown clinical utility
- Patients referred for genetic counselling regarding an identified unclassified variant (who do not fulfil Category 1 criteria) (further information can be found on the GHQ website)
If your patient does not meet the minimum referral criteria
Consider other treatment pathways or an alternative diagnosis.
If you still need to refer your patient:
- Please explain why (e.g. warning signs or symptoms, clinical modifiers, uncertain about diagnosis, etc.)
- Please note that your referral may not be accepted or may be redirected to another service
Other important information for referring practitioners
Not an exhaustive list
- List of cancer predisposition genes for which GHQ offers publicly funded confirmation testing after genetic counselling when a mutation (pathogenic/class 5 or likely pathogenic/class 4 variant) has been identified by an accredited laboratory (contact GHQ for assistance with identifying an accredited laboratory):
- AIP, APC, ATM, BAP1, BMPR1A, BRCA1, BRCA2, BRIP1, CHEK2, CDC73, CDH1, DICER1, EPCAM, MEN1, MLH1, MSH2, MSH6, MUTYH, PALB2, POLD1, POLE, PMS2, PTEN, RAD51C, RAD51D, RB1, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHC, SDHD, SMAD4, SMARCB1, STK11, TP53, VHL
- A case by case decision will be made about the clinical utility of offering confirmation testing for genes/variants not listed above.
- GHQ also offers publicly funded clinical confirmation testing after genetic counselling when a mutation (pathogenic/class 5 or likely pathogenic/class 4 variant) has been identified in one of the genes listed above in a research study. Any planned research studies involving germline genetic testing of cancer predisposition genes should be discussed with GHQ prior to commencement.
Referral requirements
A referral may be rejected without the following information.
Send referral
Hotline: 1300 364 938
Fax: 1300 364 952
Electronic: eReferral system
Mail: Metro North Central Patient Intake
Aspley Community Centre
776 Zillmere Road
ASPLEY QLD 4034
Health pathways
Access to Health Pathways is free for clinicians in Metro North Brisbane.
For login details email:
healthpathways
Login to Brisbane North Health Pathways:
brisbanenorth.
Resources
Clinical resources
- Named Referral Information Sheet
- Outpatient clinic information
- General referral criteria
- eReferral template